Cargando…

Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy

This paper reports on the reasons why patients agreed to or declined entry into randomized trials of cancer following discussions conducted by clinicians in both District General and University Hospitals. Two hundred and four patients completed a 16-item questionnaire following the consultation, of...

Descripción completa

Detalles Bibliográficos
Autores principales: Jenkins, V, Fallowfield, L
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2000
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363224/
https://www.ncbi.nlm.nih.gov/pubmed/10839291
http://dx.doi.org/10.1054/bjoc.2000.1142
_version_ 1782153650593857536
author Jenkins, V
Fallowfield, L
author_facet Jenkins, V
Fallowfield, L
author_sort Jenkins, V
collection PubMed
description This paper reports on the reasons why patients agreed to or declined entry into randomized trials of cancer following discussions conducted by clinicians in both District General and University Hospitals. Two hundred and four patients completed a 16-item questionnaire following the consultation, of these 112 (55%) were women with breast cancer. Overall results showed that 147 (72.1%) patients accepted entry to a randomized clinical trial (RCT). The main reasons nominated for participating in a trial were that ‘others will benefit’ (23.1%) and ‘trust in the doctor’ (21.1%). One of the main reasons for declining trial entry was that patients were ‘worried about randomization’ (19.6%). There was a significantly higher acceptance rate for trials providing active treatment in every arm 98 (80.6%) compared with those trials with a no treatment arm 46 (60.5%), χ(2)test P = 0.003. The study outlines a number of factors that appear to influence a patient’s decision to accept or decline entry into an RCT of cancer therapy. An important factor is whether or not the trial offers active treatment in all arms of the study. Communication that promotes trust and confidence in the doctor is also a powerful motivating influence. © 2000 Cancer Research Campaign
format Text
id pubmed-2363224
institution National Center for Biotechnology Information
language English
publishDate 2000
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23632242009-09-10 Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy Jenkins, V Fallowfield, L Br J Cancer Regular Article This paper reports on the reasons why patients agreed to or declined entry into randomized trials of cancer following discussions conducted by clinicians in both District General and University Hospitals. Two hundred and four patients completed a 16-item questionnaire following the consultation, of these 112 (55%) were women with breast cancer. Overall results showed that 147 (72.1%) patients accepted entry to a randomized clinical trial (RCT). The main reasons nominated for participating in a trial were that ‘others will benefit’ (23.1%) and ‘trust in the doctor’ (21.1%). One of the main reasons for declining trial entry was that patients were ‘worried about randomization’ (19.6%). There was a significantly higher acceptance rate for trials providing active treatment in every arm 98 (80.6%) compared with those trials with a no treatment arm 46 (60.5%), χ(2)test P = 0.003. The study outlines a number of factors that appear to influence a patient’s decision to accept or decline entry into an RCT of cancer therapy. An important factor is whether or not the trial offers active treatment in all arms of the study. Communication that promotes trust and confidence in the doctor is also a powerful motivating influence. © 2000 Cancer Research Campaign Nature Publishing Group 2000-06 /pmc/articles/PMC2363224/ /pubmed/10839291 http://dx.doi.org/10.1054/bjoc.2000.1142 Text en Copyright © 2000 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Jenkins, V
Fallowfield, L
Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy
title Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy
title_full Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy
title_fullStr Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy
title_full_unstemmed Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy
title_short Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy
title_sort reasons for accepting or declining to participate in randomized clinical trials for cancer therapy
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363224/
https://www.ncbi.nlm.nih.gov/pubmed/10839291
http://dx.doi.org/10.1054/bjoc.2000.1142
work_keys_str_mv AT jenkinsv reasonsforacceptingordecliningtoparticipateinrandomizedclinicaltrialsforcancertherapy
AT fallowfieldl reasonsforacceptingordecliningtoparticipateinrandomizedclinicaltrialsforcancertherapy